Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enzolytics Inc (OP: ENZC )

0.0009 -0.0001 (-10.00%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,020,814
Open 0.0009
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0010
Today's Range 0.0009 - 0.0010
52wk Range 0.0008 - 0.0270
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bulgarian Academy of Sciences Issues Report on Results of Its In Vivo Testing of IPF as an Immunomodulator
Via ACCESSWIRE
Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences and Enzolytics, Inc. Execute Three Year Agreement
Via ACCESSWIRE

Performance

YTD
-95.36%
-95.36%
1 Month
-40.00%
-40.00%
3 Month
-70.97%
-70.97%
6 Month
-73.53%
-73.53%
1 Year
-96.47%
-96.47%

More News

Read More
Final Report From the National Centre of Infectious and Parasitic Diseases Concludes Lyophilized Pepsin Significantly Reduces the Survival and Proliferation of Growth in Specific Cancer Cells
Via ACCESSWIRE
Penny Stocks to Watch August 2024: SPZI, RJDG, HIRU, AABB more inside…
Via AB Newswire
Enzolytics, Inc. and the Bulgarian Academy of Sciences Initiate a Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/AIDS Applications
Via ACCESSWIRE
Enzolytics, Inc. Enters Into Collaboration Agreement With Manufacturer Elimus Ltd.
Via ACCESSWIRE
Enzolytics, Inc. Enters Into Exclusive Worldwide License for Patented Immunotherapy Cancer Treatment
Via ACCESSWIRE
Enzolytics, Inc. Announces Letter of Intent for Exclusive Licensing Agreement for Patented Nitric Oxide Formulation
Via ACCESSWIRE
Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release
Via ACCESSWIRE
Enzolytics, Inc. Poised to Invest Alongside Sagaliam Acquisition Corp in Revolutionary Room Temperature SPAD Technology
Via ACCESSWIRE
Spotlight: Stocks Under One Penny Key Updates SPZI, HNRC, ENZC, HALB, BIEI
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment
Via ACCESSWIRE
Enzolytics Inc. Announces Dismissal of The Dimitar Savov Lawsuit in Nevada
Via ACCESSWIRE
Update on Formulation of New Business Strategy
Via ACCESSWIRE
Enzolytics Announces the Signing of the Business Combination Agreement with Sagaliam Acquisition Corp (SAGA)
Via ACCESSWIRE
Patient Population for the Clinical Trials of ITV-1 has been Established by the European Medicines Agency ("EMA")
Via ACCESSWIRE
Stocks Under 5¢ To Watch Now! HNRC, HALB, ENZC, SNNC, SPZI
Via AB Newswire
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Economy
OTC Stocks to Watch in February: CLNV, HNRC, ENZC, GEVI, PBIO
Via AB Newswire
Topics Artificial Intelligence Bonds
Exposures Artificial Intelligence Debt Markets
“Exploring Market Opportunities Stocks to Watch Under 5¢ Now: CLNV, ENZC, HNRC, HALB, SPZI”
Via AB Newswire
Topics Artificial Intelligence Energy
Exposures Artificial Intelligence Fossil Fuels
Enzolytics, Inc. Announces Partnership With the Khalpey AI Lab To Forge the Future of Multi-Organ Remodeling and Rejuvenation With a Strategic Focus on Longevity
Via ACCESSWIRE
Penny Stocks, Shifts in Trends, Notable Performances, and Strategic Developments, Opportunities: CLNV, HALB, SPZI, HNRC, ENZC
Via AB Newswire
Topics Bonds Economy
Exposures Debt Markets Economy
Virogentics, Inc. Receives Permit for Export to Africa of the ITV-1 Immunotherapy Solidifying the Scheduled Administration of the Treatment
Via ACCESSWIRE
Enzolytics, Inc. Files Amended December 31, 2022 OTC Report with Audited Financials and Unaudited September 30, 2023 Quarterly Disclosure
Via ACCESSWIRE
Biogenysis, Inc. Announces Partnering with Khalpey AI Lab and Contenta, Ltd. to Incorporate AI in Microbiome Analysis to Identify Biomarkers for Use in Accurately Predicting Alzheimer's Disease Onset and Prevention.
Via ACCESSWIRE
Biogenysis’ International Patent Application, Covering Its Anti-SARS-CoV-2 Monoclonal Antibodies, Advances to Prosecution in Europe and as a U.S. National Stage Application.
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.